Skip to content
    Real-World Studies

    Pneumonectomy Outcomes After Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer

    Caturegli et alJTCVS open

    Pneumonectomy Outcomes After Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer
    A retrospective National Cancer Database study evaluated surgical outcomes in adult patients diagnosed between 2018 and 2023 with clinical stage I to III lung adenocarcinoma or squamous cell carcinoma who received neoadjuvant chemoimmunotherapy followed by lobectomy or pneumonectomy. The study evaluated 2,703 lobectomies (94%) and 173 pneumonectomies (6%). Patients who underwent pneumonectomy presented with more advanced T stage (64% vs 47% T3+, P < .001) but a lower comorbidity burden (71% vs 58% Charlson-Deyo score of 0, P = .01).
    Pneumonectomy was associated with significantly higher rates of 30-day unplanned readmission (9% vs 4%, P = .001) and R1+ resection margins (7.1% vs 3.9%, P = .046). However, 90-day mortality did not differ significantly between the groups (<4.5% for pneumonectomy vs 2% for lobectomy, P = .24).
    Kaplan-Meier analysis revealed unadjusted 3-year overall survival of 80% for pneumonectomy compared to 82% for lobectomy (P = .08). Following propensity score matching for baseline patient and tumor characteristics, 3-year overall survival remained similar at 79% for pneumonectomy versus 78% for lobectomy (P = .19). On multivariable Cox proportional hazards modeling, pneumonectomy was associated with an elevated hazard ratio of mortality that was not statistically significant (reported as odds ratio, 1.56; 95% CI, 0.91-2.68; P = .09). The authors concluded that pneumonectomy after induction chemoimmunotherapy demonstrated comparable early survival with lobectomy among selected patients and appears reasonable in appropriate candidates.

    Key Takeaways

    • Propensity-matched 3-year overall survival was comparable between pneumonectomy and lobectomy after neoadjuvant chemoimmunotherapy (79% vs 78%, P = .19), with 90-day mortality also showing no statistically significant difference (<4.5% vs 2%, P = .24).
    • Patients undergoing pneumonectomy experienced higher rates of 30-day unplanned readmission (9% vs 4%, P = .001) and R1+ resection margins (7.1% vs 3.9%, P = .046) compared with those undergoing lobectomy.